Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00002061
NCT00002061
Completed
Not Applicable

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy

Newport Pharmaceuticals International1 site in 1 countryAugust 31, 2001
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsLymphatic DiseaseHIV Infections
DrugsInosine pranobex

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lymphatic Disease
Sponsor
Newport Pharmaceuticals International
Locations
1
Status
Completed
Last Updated
20 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of the 28 days of treatment), measured by one or more of the following immunologic parameters:

  • Increase in natural killer (NK) cell activity.
  • Increase in total T-cells (OKT-11).
  • Increases in absolute number and percentages of T-helper cells (OKT-4).
Registry
clinicaltrials.gov
Start Date
August 31, 2001
End Date
TBD
Last Updated
20 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Newport Pharmaceuticals International

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node DiseaseLymphatic DiseaseHIV Infections
NCT00002296Newport Pharmaceuticals International
Completed
Phase 3
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's AtaxiaFriedreich's Ataxia
NCT02415127Amgen92
Completed
Phase 3
Study of CM310 in Subjects With Allergic RhinitisAllergic Rhinitis
NCT05908032Keymed Biosciences Co.Ltd108
Completed
Phase 3
A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLCExtensive-stage Small-cell Lung Cancer
NCT04878016Lee's Pharmaceutical Limited498
Completed
Phase 3
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell CarcinomaAdvanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
NCT03829969Shanghai Junshi Bioscience Co., Ltd.514